Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2006

View Archived Issues

Drug bioavailability increased by tight junction modulator AT-1002 in preclinical studies

Enrollment begins in pivotal study of NOV-002 in advanced NSCLC

Watson completes acquisition of Andrx

Accentia set to open enrollment in phase III chronic sinusitis study of SinuNase

Antigen Express' synthetic avian influenza vaccine to begin clinical trials

Abbott to acquire Kos

Phase III trials of tramiprosate cleared to continue

Ziopharm acquires indibulin from Baxter

Survival data for Erbitux in metastatic colorectal cancer

Numax achieves primary endpoint in RSV study

CRx-102 demonstrates positive effect in rheumatoid arthritis

Bremelanotide effective in diabetic and nondiabetic erectile dysfunction patients

Positive interim survival results for picoplatin in SCLC

Celgosivir combination therapy shows benefit in chronic HCV nonresponders

Enrollment advances in phase III Riquent study

Long-term efficacy of entecavir in hepatitis B reported

Respiratory syncytial virus/parainfluenza virus type 3 vaccine safe in phase I study

Studies assess effects of PF-03491390 in hepatitis C, liver transplantation

Several new studies of rotigotine presented

Phase III results show improvements in COPD measures with arformoterol

Ambrisentan does not interact with warfarin or sildenafil

BLA filing for Thrombin

Voraxaze BLA withdrawn, with plans to resubmit

Duetact now available in U.S.

orBec filed in Europe for GI GVHD

Recent Dabur patent describes novel peptide-based therapeutic agents for alopecia

Recent patents describe new antidiabetic agents

Recent patents cover new therapeutic agents for cancer

Positive phase Ib results for AZD-6244 against solid tumors, phase II trials initiated

Preclinical data on liposomal irinotecan, IHL-305, versus irinotecan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...